Drug Development And ApprovalThe potential approval for Donanemab to treat Alzheimer’s disease could significantly influence the company's stock price positively.
Manufacturing And Supply ImprovementsThe FDA issued a press release stating that the shortage of tirzepatide has been resolved, confirming that the manufacturer's product availability and manufacturing capacity can meet present and projected national demand.
Market Growth And SalesEli Lilly is expected to see significant growth in sales, especially with the ramp-up of Mounjaro and the launch of Zepbound.